The Sunshine Act: Promising Clarity & Providing Confusion

The logic behind the Sunshine Act says that providing clarity on any money that pharma and device makers pay to doctors and hospitals will reduce the occurrence or appearance of corruption. .

The idea is that by making those payments a matter of public record makes it undesirable for companies to try to influence medical experts.

Continue reading

Docs advocate for novel biosimilar names


Ever since the FDA drafted a set of rules for biosimilars in 2012, a debate has been raging over whether those drugs should carry the same generic names as the products they emulate. Now, some doctors are weighing in on the issue, urging the FDA to require biosimilars to have different names than branded biotech drugs.

Continue reading

Studies Show Economic Benefit to Specialty Pharma Drugs like Sovaldi #reducethecopay


On July 16th I wrote a piece about hi-copay specialty tiers, and how insurance companies are using them to restrict access to specialty pharma. In the hi-copay specialty tier, instead of pay a flat fee for the medications, patients must instead pay for a percentage of the drug cost, anywhere from 20%-50%.

Continue reading

Politicians Shouldn’t Question Drug Costs But Rather Their Value. Lessons From Soliris And Sovaldi.

Originally posted on Forbes